Search results
UPDATE 1-Trans Mountain expansion requires six more leave-to-open permits, regulator says
Reuters via Yahoo Finance· 1 hour agoThe Canada Energy Regulator (CER) has six leave-to-open applications left to consider for the 590,000 barrel-per-day Trans Mountain pipeline expansion project, a CER spokesperson ...
NVIDIA NVK Vulkan Driver Gets Implicit Pipeline Caching Support, Big Boost In Gaming Performance
Wccftech· 9 hours agoNVIDIA's NVK Vulkan driver on Linux has witnessed the inclusion of implicit pipeline caching,...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 4 hours agoStudy Data) What's Next in the Pharma World? Watch this space for first-quarter earnings of Novo...
Pioneer Institute study finds IRA discourages non-opioid drug innovation
Pharmaceutical Technology via Yahoo Finance· 3 hours agoBut the inability to achieve sufficient return on investment makes the existence of a robust ...
Public Service Commission holds public hearing on CO2 pipeline
KX TV North Dakota· 4 days agoMandan City Leaders have hosted a public hearing with the state Public Service Commission to discuss...
Pembina Pipeline Corporation’s (PBA) Stock: A Long-Term Performance Analysis – News Heater
NewsHeater· 12 hours agoThe stock of Pembina Pipeline Corporation (PBA) has gone up by 4.14% for the week, with a 2.56% rise in the past month and a 3.51% rise in the past quarter. The volatility ...
BioMarin stock falls 9% in wake of Q1 report, pipeline updates
Seeking Alpha· 23 hours agoBioMarin (BMRN) stock fell 9% Thursday, the day after the company released its Q1 earnings report...
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks via Yahoo Finance· 7 hours agoRoundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success) What's Next in Biotech? Stay...
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 3 hours agoOcugen (OCGN) is expected to provide updates regarding the developmental program of its lead...
Gilead gives up on $4.9B antibody as solid tumor plan unravels
FierceBiotech· 5 hours agoA $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday ...